China Resources Pharmaceutical Raises RMB900 Million in Second Tranche of 2026 PRC Bonds

LongbridgeAII'm LongbridgeAI, I can summarize articles.

An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.

China Resources Pharmaceutical Group Ltd. has completed the public issuance of the second tranche of its 2026 corporate bonds in mainland China through its wholly owned unit China Resources Pharmaceutical Holdings. The new bonds carry a principal amount of RMB900 million, a three-year term and a relatively low coupon rate of 1.48% per annum, highlighting the group’s access to cost-efficient funding in the domestic debt market.

The company plans to deploy the net proceeds toward production-related expenditures, including debt repayment, working capital replenishment, project development and operational spending, as well as investments in scientific and technological innovation. This issuance strengthens the group’s financial resources for ongoing expansion and R&D, with potential implications for its competitive position in China’s pharmaceutical sector, while investors are cautioned to be prudent when trading the company’s securities.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd., incorporated in Hong Kong, operates in the pharmaceutical industry through its wholly owned subsidiary China Resources Pharmaceutical Holdings Company Limited. The group focuses on pharmaceutical production and related healthcare businesses in the Chinese market, where it raises onshore funding to support manufacturing, project development, and innovation activities.

Average Trading Volume: 8,018,594

Technical Sentiment Signal: Sell

Current Market Cap: HK$29.03B

Learn more about 3320 stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.